<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mamm Genome</journal-id><journal-title>Mammalian Genome</journal-title><issn pub-type="ppub">0938-8990</issn><issn pub-type="epub">1432-1777</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18592312</article-id><article-id pub-id-type="publisher-id">9117</article-id><article-id pub-id-type="doi">10.1007/s00335-008-9117-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Banks</surname><given-names>Gareth T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuta</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Isaacs</surname><given-names>Adrian M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fisher</surname><given-names>Elizabeth M. C.</given-names></name><address><phone>+44-207-6762037</phone><email>e.fisher@prion.ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG UK </aff><aff id="Aff2"><label>2</label>MRC Prion Unit, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG UK </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>7</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2008</year></pub-date><volume>19</volume><issue>5</issue><fpage>299</fpage><lpage>305</lpage><history><date date-type="received"><day>2</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2008</copyright-statement></permissions><abstract><p>In 2006 the protein TDP-43 was identified as the major ubiquitinated component deposited in the inclusion bodies found in two human neurodegenerative diseases, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The pathogenesis of both disorders is unclear, although they are related by having some overlap of symptoms and now by the shared histopathology of TDP-43 deposition. Now, in 2008, several papers have been published in quick succession describing mutations in the TDP-43 gene, showing they can be a primary cause of amyotrophic lateral sclerosis. There are many precedents in neurodegenerative disease in which rare single-gene mutations have given great insight into understanding disease processes, which is why the TDP-43 mutations are potentially very important.</p></abstract><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC 2008</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Rapidly rising life expectancy is forcing many of the world&#x02019;s societies to see neurodegenerative diseases as a wider social and economic issue. Such diseases have always been devastating for sufferers and their carers, but aging societies are facing a broader burden resulting from the lack of effective treatments. There is hope for disorders such as Alzheimer disease (AD), where now we have a good understanding of pathogenesis and novel treatments are on the horizon. However, two neurodegenerative disorders that remain in urgent need of attention, and that mainly but not exclusively affect the aging population, are amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).</p><p>ALS is the third most common neurodegenerative cause of adult death after AD and Parkinson disease (<ext-link ext-link-type="uri" xlink:href="http://www.statistics.gov.uk/StatBase">http://www.statistics.gov.uk/StatBase</ext-link>) and the lifetime risk of dying from ALS lies between 1/400 and 1/1000 (Boillee et&#x000a0;al. <xref ref-type="bibr" rid="CR6">2006</xref>; Pasinelli and Brown <xref ref-type="bibr" rid="CR35">2006</xref>), and in the UK 1 in 400 death certificates is issued for &#x0201c;motor neuron disease&#x0201d; (J. Stevens, personal communication). In ALS the upper motor neurons that run from the brain into the spinal cord and the lower motor neurons that extend from the spinal cord out to the muscles degenerate, leading inexorably to paralysis and death, typically within 3&#x02013;5 years of diagnosis (Boillee et&#x000a0;al. <xref ref-type="bibr" rid="CR6">2006</xref>; Pasinelli and Brown <xref ref-type="bibr" rid="CR35">2006</xref>; Schymick et&#x000a0;al. <xref ref-type="bibr" rid="CR43">2007</xref>; Valdmanis and Rouleau <xref ref-type="bibr" rid="CR50">2008</xref>). Intellect usually remains intact and no effective treatments are available. Up to approximately 10% of ALS is familial (FALS), usually autosomal dominant, and mutations in the ubiquitously expressed enzyme superoxide dismutase 1 (SOD1) are causative in less than 20% of FALS (Deng et&#x000a0;al. <xref ref-type="bibr" rid="CR11">1993</xref>; Rosen et&#x000a0;al. <xref ref-type="bibr" rid="CR41">1993</xref>) and in approximately 1% of sporadic ALS (SALS) (Pasinelli and Brown <xref ref-type="bibr" rid="CR35">2006</xref>). Other rare ALS mutant genes are known, usually associated with variants of ALS rather than the classic typical midlife onset disease (Boillee et&#x000a0;al. <xref ref-type="bibr" rid="CR6">2006</xref>; Pasinelli and Brown <xref ref-type="bibr" rid="CR35">2006</xref>; Schymick et&#x000a0;al. <xref ref-type="bibr" rid="CR43">2007</xref>; Valdmanis and Rouleau <xref ref-type="bibr" rid="CR50">2008</xref>).</p><p>FTLD is the most common cause of presenile (below 65 years of age) dementia after AD (Forman et&#x000a0;al. <xref ref-type="bibr" rid="CR13">2007</xref>; Harvey et&#x000a0;al. <xref ref-type="bibr" rid="CR19">2003</xref>; Ratnavalli et&#x000a0;al. <xref ref-type="bibr" rid="CR38">2002</xref>). Affected individuals have a range of characteristic traits that reflect degeneration in the frontal and temporal lobes of the brain&#x02014;the areas that control behavior, emotions, and language. Early symptoms typically manifest as language difficulties and inappropriate behavior (Neary et&#x000a0;al. <xref ref-type="bibr" rid="CR31">1998</xref>). Up to 40% of FTLD is thought to be familial with genetically heterogeneous causes. Causative mutations have been identified in several genes, including those encoding tau (Hutton et&#x000a0;al. <xref ref-type="bibr" rid="CR22">1998</xref>; Poorkaj et&#x000a0;al. <xref ref-type="bibr" rid="CR37">1998</xref>; Spillantini et&#x000a0;al. <xref ref-type="bibr" rid="CR46">1998</xref>), charged multivesicular body protein 2B (<italic>CHMP2B</italic>) (Skibinski et&#x000a0;al. <xref ref-type="bibr" rid="CR44">2005</xref>), and progranulin (<italic>GRN</italic>) (Baker et&#x000a0;al. <xref ref-type="bibr" rid="CR5">2006</xref>; Cruts et&#x000a0;al. <xref ref-type="bibr" rid="CR10">2006</xref>), and others remain to be found. Mutations have also been identified in the valosin-containing protein (<italic>VCP</italic>) gene in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia, in which frontotemporal dementia can be, but is not always, a feature (Watts et&#x000a0;al. <xref ref-type="bibr" rid="CR52">2004</xref>).</p><p>At first glance ALS and FTLD appear to be different disorders; however, clinicians have noted for some time that there are overlaps. FTLD symptoms are reported in up to 20% of ALS cases (Valdmanis and Rouleau <xref ref-type="bibr" rid="CR50">2008</xref>; Van Deerlin et&#x000a0;al. <xref ref-type="bibr" rid="CR51">2008</xref>) and there are other intriguing connections such as families that segregate both disorders (Morita et&#x000a0;al. <xref ref-type="bibr" rid="CR29">2006</xref>; Valdmanis et&#x000a0;al. <xref ref-type="bibr" rid="CR49">2007</xref>) and imaging studies which show frontal deficits in ALS patients (Kato et&#x000a0;al. <xref ref-type="bibr" rid="CR25">1993</xref>). A recent study has shown that progranulin is a modifier of ALS disease progression (Sleegers et&#x000a0;al. <xref ref-type="bibr" rid="CR45">2008</xref>), although this was not replicated in another study (Pickering-Brown et&#x000a0;al. <xref ref-type="bibr" rid="CR36">2008</xref>).</p><p>Importantly, in common with several other neurodegenerative disorders, ALS and FTLD both present with aggregates of misfolded proteins in the cytoplasm and/or nucleus of neurons. Ubiquitinated inclusion bodies have been reported in the cytoplasm of neurons of both SALS and FALS cases and in mutant <italic>SOD1</italic> transgenic mice that model FALS (for further discussion see Boillee et&#x000a0;al. <xref ref-type="bibr" rid="CR6">2006</xref>; Pasinelli and Brown <xref ref-type="bibr" rid="CR35">2006</xref>). FTLD is subdivided into two classes based on the content of the inclusion bodies: (1) those with tau-positive and ubiquitin-negative inclusions (tauopathies) and (2) more common forms with ubiquitinated but tau-negative inclusions known as FTLD-U, including <italic>PGRN</italic>, <italic>VCP</italic>, and <italic>CHMP2B</italic> mutations (reviewed in Mackenzie and Rademakers <xref ref-type="bibr" rid="CR28">2007</xref>). ALS and FTLD-U cases both present with cytoplasmic ubiquitin-positive, tau-negative inclusions indicating that there are at least some common pathway(s) involved in the pathogenesis of these diseases.</p></sec><sec id="Sec2"><title><bold>TDP-43&#x02014;the new kid on the block</bold></title><p>Research into ALS and FTLD-U was radically redirected by the appearance of a new player in 2006. In that year, Neumann, Trojanowski, Lee, and colleagues provided a molecular connection between these disorders by finding that a protein called the TAR DNA-binding protein (TDP-43) is the major protein in the inclusion bodies in both disorders (Neumann et&#x000a0;al. <xref ref-type="bibr" rid="CR32">2006</xref>), which was quickly confirmed (Arai et&#x000a0;al. <xref ref-type="bibr" rid="CR2">2006</xref>). Some authors now refer to the TDP-43 inclusion positive types of ALS and FTLD-U as different forms of the same neurodegenerative disorder: TDP-43 proteinopathy (Cairns et&#x000a0;al. <xref ref-type="bibr" rid="CR9">2007</xref>; Kwong et&#x000a0;al. <xref ref-type="bibr" rid="CR26">2008</xref>; Winton et&#x000a0;al. <xref ref-type="bibr" rid="CR53">2008</xref>). TDP-43 positive inclusions have now also been reported in cases of Alzheimer disease, Pick disease, dementia with Lewy bodies, and other neurodegenerative disorders, and are seen in glia as well as neurons (Amador-Ortiz et&#x000a0;al. <xref ref-type="bibr" rid="CR1">2007</xref>; Freeman et&#x000a0;al. <xref ref-type="bibr" rid="CR14">2008</xref>; Geser et&#x000a0;al. <xref ref-type="bibr" rid="CR15">2008</xref>; Hasegawa et&#x000a0;al. <xref ref-type="bibr" rid="CR20">2007</xref>; Higashi et&#x000a0;al. <xref ref-type="bibr" rid="CR21">2007</xref>; Nakashima-Yasuda et&#x000a0;al. <xref ref-type="bibr" rid="CR30">2007</xref>; Neumann et&#x000a0;al. <xref ref-type="bibr" rid="CR33">2007</xref>).</p><p>TDP-43 is a 414-residue, 43-kDa protein, first identified as a binding partner of the TAR DNA element of the human immunodeficiency virus (Ou et&#x000a0;al. <xref ref-type="bibr" rid="CR34">1995</xref>). Currently we know that TDP-43 is a ubiquitously expressed, highly conserved nuclear protein encoded by a 6-exon gene (<italic>TARDBP</italic> on human chromosome 1p36.2). The protein consists of two RNA recognition motifs and a glycine-rich domain (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). It is found in nuclear bodies, colocalized with SMN and gemin proteins, and may function as a transcriptional repressor and as an activator of exon skipping, or in other roles such as in miRNA biogenesis, apoptosis, and cell division (Ayala et&#x000a0;al. <xref ref-type="bibr" rid="CR4">2005</xref>, <xref ref-type="bibr" rid="CR3">2008</xref>; Buratti et&#x000a0;al. <xref ref-type="bibr" rid="CR8">2001</xref>; Johnson et&#x000a0;al. <xref ref-type="bibr" rid="CR23">2008</xref>; Winton et&#x000a0;al. <xref ref-type="bibr" rid="CR53">2008</xref>). In the TDP-43 proteinopathies TDP-43 is depleted from the nucleus and is sequestered as hyperphosphorylated insoluble aggregates in the nucleus, perikarya, and dystrophic neurites (Neumann et&#x000a0;al. <xref ref-type="bibr" rid="CR32">2006</xref>). Perturbation of the trafficking of TDP-43 between the nucleus and cytoplasm is thought to lead to the formation of these aggregates; brain samples from both ALS and FTLD-U are enriched for a smaller (&#x0223c;25 kDa) phosphorylated C-terminal fragment and high-molecular-weight ubiquitinated species (Neumann et&#x000a0;al. <xref ref-type="bibr" rid="CR32">2006</xref>; Winton et&#x000a0;al. <xref ref-type="bibr" rid="CR53">2008</xref>). Inhibition of autophagy can also lead to the relocalization of TDP-43 from the nucleus to the cytoplasm in vitro (Filimonenko et&#x000a0;al. <xref ref-type="bibr" rid="CR12">2007</xref>). <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et&#x000a0;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#x000a0;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#x000a0;al. <xref ref-type="bibr" rid="CR54">2008</xref>)</p></caption><graphic position="anchor" xlink:href="335_2008_9117_Fig1_HTML" id="MO1"/></fig></p><p>Intriguingly, while TDP-43 is deposited in sporadic and familial FTLD-U and in sporadic and non-SOD1 familial ALS (Kwong et&#x000a0;al. <xref ref-type="bibr" rid="CR26">2008</xref>; Neumann et&#x000a0;al. <xref ref-type="bibr" rid="CR32">2006</xref>), it is not found in inclusions in SOD1 FALS (Mackenzie et&#x000a0;al. <xref ref-type="bibr" rid="CR27">2007</xref>; Tan et&#x000a0;al. <xref ref-type="bibr" rid="CR48">2007</xref>) or in the <italic>SOD1</italic><sup><italic>G93A</italic></sup>, <italic>SOD1</italic><sup><italic>G37R</italic></sup>, and <italic>SOD1</italic><sup><italic>G85R</italic></sup> transgenic mouse models of FALS (Robertson et&#x000a0;al. <xref ref-type="bibr" rid="CR39">2007</xref>).</p></sec><sec id="Sec3"><title>TDP-43 is a criminal, not just a bystander</title><p>The identification of TDP-43 in ALS and FTLD-U inclusion bodies immediately led to surveys of patient cohorts to find either association with or mutations in the gene. All returned with negative results (e.g., see Gijselinck et&#x000a0;al. <xref ref-type="bibr" rid="CR16">2007</xref>; Rollinson et&#x000a0;al. <xref ref-type="bibr" rid="CR40">2007</xref>; Schumacher et&#x000a0;al. <xref ref-type="bibr" rid="CR42">2007</xref>), leading to the reasonable conclusion that TDP-43 deposition may simply be a <italic>consequence</italic> of disease and therefore possibly of less interest in providing novel insight into the <italic>cause</italic> of these diseases. However, in 2008 all this has changed with the publication of five articles, all of which report rare TDP-43 mutations in sporadic and familial ALS in patients of different ethnicities (mainly but not exclusively Caucasian) (Gitcho et&#x000a0;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#x000a0;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#x000a0;al. <xref ref-type="bibr" rid="CR54">2008</xref>). In summary (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), all the mutations lie in exon 6 except for one in exon 4. The FALS cases are autosomal dominant with some variability in presentation, bulbar and limb onset cases, some with more or less lower motor neuron loss and different ages of onset and rates of progression, but all fairly classic FALS. No dementia is found, although Kabashi et&#x000a0;al. (<xref ref-type="bibr" rid="CR24">2008</xref>) report apathy, major anxiety, and agitation in two individuals. For cases in which postmortems have been carried out, TDP-43 deposition has been found in the brains of affected individuals (Van Deerlin et&#x000a0;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#x000a0;al. <xref ref-type="bibr" rid="CR54">2008</xref>). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Novel mutations in the gene encoding TDP-43</p></caption><graphic xlink:href="335_2008_9117_Tab1_HTML"/><table-wrap-foot><p>SALS&#x000a0;=&#x000a0;sporadic amyotrophic lateral sclerosis; FALS&#x000a0;=&#x000a0;familial amyotrophic lateral sclerosis; MND&#x000a0;=&#x000a0;motor neuron disease; <italic>GRN</italic>&#x000a0;=&#x000a0;progranulin; <italic>SOD1</italic>&#x000a0;=&#x000a0;Cu/Zn superoxide dismutase 1; <italic>MAPT</italic>&#x000a0;=&#x000a0;microtubule-associated protein tau; <italic>CHMP2B&#x000a0;=</italic>&#x000a0;chromatin modifying protein 2B; <italic>VAPB</italic>&#x000a0;=&#x000a0;synaptobrevin-associated membrane protein B; <italic>ANG</italic>&#x000a0;=&#x000a0;angiogenin; <italic>DCTN1</italic>&#x000a0;=&#x000a0;dynactin.</p><p>Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of <italic>TARDBP</italic> and one mutation lies in the first RNA binding domain (D169G)</p><p><sup>1</sup>mean age of onset, <sup>2</sup>FTLD and related disorders, see text for details, <sup>3</sup>all exons sequenced, <sup>4</sup>only the specific variants were analyzed, full sequencing was not performed, <sup>5</sup>only exon 6 sequenced, <sup>6</sup>method of detection not described, <sup>f</sup>mutation found in familial ALS, or <sup>s</sup>individuals with no known family history of ALS</p></table-wrap-foot></table-wrap></p><p>The mutations are already starting to give some insight into pathogenesis (Gitcho et&#x000a0;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#x000a0;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#x000a0;al. <xref ref-type="bibr" rid="CR54">2008</xref>). Disruption of protein interactions is one possible disease mechanism. Most mutations lie in the C-terminal, a glycine-rich region that may mediate interactions with proteins, including heterogeneous ribonucleoproteins. Also, some of the mutations found in this region could increase phosphorylation by substituting threonine or serine residues or through the creation of a new protein kinase A site (Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>). This may result in disruption of protein interactions and/or disruption of transport through the nuclear pore complex. In transfected cell lines and patient lymphocytes some variants also show a clearly increased propensity to aggregate and to produce a lower-molecular&#x02013;weight, detergent-insoluble protein product (Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Yokoseki et&#x000a0;al. <xref ref-type="bibr" rid="CR54">2008</xref>). One mutation, D169G, lies in the first RNA-binding motif and may affect RNA binding (Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>). When mutant TDP-43 is electroporated into the neural tube of developing chick embryos, two different mutations showed a reduction in rate of maturation of the neural tube with an increase in apoptotic nuclei, suggesting a toxic gain of function or dominant negative effect (Sreedharan et&#x000a0;al. <xref ref-type="bibr" rid="CR47">2008</xref>).</p><p>It is noteworthy that just one mutation lies in exon 4, within the first RNA recognition motif (RRM 1), whereas the other 13 mutations identified so far occur in exon 6, in the putative protein interaction domain. This raises the question of whether the exon 4 mutation (D169G) is a genuine pathogenic mutation and, if so, if it leads to disease via a different effect on TDP-43 function than the other mutations. D169 is a highly conserved amino acid (Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>) and the mutation was absent in 360 ethnically matched controls from France (Kabashi et&#x000a0;al. <xref ref-type="bibr" rid="CR24">2008</xref>), as well as in 872 nonethnically matched controls (700 British, 172 Australian) for which all exons of TDP-43 were sequenced in the study of Sreedharan et&#x000a0;al. (<xref ref-type="bibr" rid="CR47">2008</xref>). The absence of the mutation in a large number of controls and the evolutionary conservation of the amino acid argue for a pathogenic role; however, absence in a larger number of ethnically matched controls and functional data or the identification of further mutations in RRM 1 will be required to fully resolve this issue. If D169G is pathogenic, then it suggests that mutations in the C-terminal domain, and the RRM1 domain, which has been shown to be essential for the RNA-binding ability of TDP-43 (Buratti and Baralle. <xref ref-type="bibr" rid="CR7">2001</xref>), affect the function of TDP-43 in a similar way, such as a general loss of function, or that there are different ways to disrupt TDP-43 function and still lead to disease.</p></sec><sec id="Sec4"><title>Rare single-gene defects, protein aggregates, and neurodegeneration&#x02014;sounds familiar</title><p>The identification of the major protein in neurodegenerative disease inclusion bodies, followed by finding rare mutations in the gene encoding this protein, is a powerful route to understanding pathogenesis and is turning into a surprisingly common approach in neurodegenerative diseases. It is exemplified by the classic example of finding mutations in the amyloid precursor protein (<italic>APP</italic>) gene that encodes the Abeta peptide deposited in the plaques of Alzheimer disease; it revolutionized our understanding of AD (Hardy and Selkoe <xref ref-type="bibr" rid="CR18">2002</xref>). Similar rare dominant single-gene mutations have also been found in the proteins that aggregate in Parkinson disease, prion diseases, and tauopathies, for example, also giving us great insight into the pathogenesis of these disorders. The articles that reported on TDP-43 mutations in ALS have shifted the focus of attention on this protein from being deposited as a by-product of disease processes to actually being a causative agent that triggers the processes resulting in neuronal death. From this point investigations will proceed using transgenic and knockout mice and a variety of different cellular systems to understand the link between mutation and disease.</p><p>Many questions need to be addressed, such as does TDP-43 take on a toxic gain of function when mutated in ALS, as happens with <italic>SOD1</italic> mutations in ALS? Will TDP-43 mutations be found in cases of FTLD-U, and if not, why not? How important is timing? Does having a germline TDP-43 mutation give rise to ALS which might develop into FTLD-U if individuals lived long enough? Another question is: What separates TDP-43 ALS from SOD1 ALS? These two diseases are very similar at a clinical level, but clearly different pathways are affected for at least some of the pathogenesis. We assume that there are many parallel cellular pathways, which, if disrupted can lead to the same outcome. TDP-43 ALS and SOD1 ALS may allow the investigation of this phenomenon.</p><p>The new mutations found in TDP-43 are a breakthrough for ALS and FTLD-U research and we are looking forward to seeing what new discoveries they herald to help us treat and ultimately cure these terrible neurodegenerative diseases.</p></sec></body><back><ack><p>For brevity we have cited recent review articles rather than original literature. Also, we have used the most frequently used abbreviation for the TDP-43 protein, which does not conform to human or mouse gene nomenclature rules. We thank Simon Mead and James Stevens for comments and Ray Young for graphics. These authors are supported by the Wellcome Trust, the ENDOCYTE Research and Training Network funded by the European Union, and the UK Medical Research Council.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amador-Ortiz</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Personett</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><etal/></person-group><article-title>TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>2007</year><volume>61</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/ana.21154</pub-id></citation><citation citation-type="display-unstructured">Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P et&#x000a0;al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x02019;s disease. Ann Neurol 61:435&#x02013;445 <pub-id pub-id-type="pmid">17469117</pub-id></citation></ref><ref id="CR2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>351</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.10.093</pub-id></citation><citation citation-type="display-unstructured">Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T et&#x000a0;al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602&#x02013;611 <pub-id pub-id-type="pmid">17084815</pub-id></citation></ref><ref id="CR3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>YM</given-names></name><name><surname>Pantano</surname><given-names>S</given-names></name><name><surname>D&#x02019;Ambrogio</surname><given-names>A</given-names></name><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Brindisi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human, <italic>Drosophila</italic>, and <italic>C. elegans</italic> TDP43: nucleic acid binding properties and splicing regulatory function</article-title><source>J Mol Biol</source><year>2005</year><volume>348</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.02.038</pub-id></citation><citation citation-type="display-unstructured">Ayala YM, Pantano S, D&#x02019;Ambrogio A, Buratti E, Brindisi A et&#x000a0;al (2005) Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol 348:575&#x02013;588 <pub-id pub-id-type="pmid">15826655</pub-id></citation></ref><ref id="CR4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>YM</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group><article-title>TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>3785</fpage><lpage>3789</lpage><pub-id pub-id-type="doi">10.1073/pnas.0800546105</pub-id></citation><citation citation-type="display-unstructured">Ayala YM, Misteli T, Baralle FE (2008) TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 105:3785&#x02013;3789 <pub-id pub-id-type="pmid">18305152</pub-id></citation></ref><ref id="CR5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Pickering-Brown</surname><given-names>SM</given-names></name><name><surname>Gass</surname><given-names>J</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17</article-title><source>Nature</source><year>2006</year><volume>442</volume><fpage>916</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1038/nature05016</pub-id></citation><citation citation-type="display-unstructured">Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R et&#x000a0;al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916&#x02013;919 <pub-id pub-id-type="pmid">16862116</pub-id></citation></ref><ref id="CR6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boillee</surname><given-names>S</given-names></name><name><surname>Vande</surname><given-names>VC</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><article-title>ALS: a disease of motor neurons and their nonneuronal neighbors</article-title><source>Neuron</source><year>2006</year><volume>52</volume><fpage>39</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.018</pub-id></citation><citation citation-type="display-unstructured">Boillee S, Vande VC, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52:39&#x02013;59 <pub-id pub-id-type="pmid">17015226</pub-id></citation></ref><ref id="CR7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group><article-title>Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1074/jbc.M104236200</pub-id></citation><citation citation-type="display-unstructured">Buratti E, Baralle FE (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276:36 </citation></ref><ref id="CR8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Dork</surname><given-names>T</given-names></name><name><surname>Zuccato</surname><given-names>E</given-names></name><name><surname>Pagani</surname><given-names>F</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>1774</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.7.1774</pub-id></citation><citation citation-type="display-unstructured">Buratti E, Dork T, Zuccato E, Pagani F, Romano M et&#x000a0;al (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20:1774&#x02013;1784 <pub-id pub-id-type="pmid">11285240</pub-id></citation></ref><ref id="CR9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Holm</surname><given-names>IE</given-names></name><name><surname>Troost</surname><given-names>D</given-names></name><etal/></person-group><article-title>TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions</article-title><source>Am J Pathol</source><year>2007</year><volume>171</volume><fpage>227</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.070182</pub-id></citation><citation citation-type="display-unstructured">Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D et&#x000a0;al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227&#x02013;240 <pub-id pub-id-type="pmid">17591968</pub-id></citation></ref><ref id="CR10"><citation citation-type="other">Cruts M, Gijselinck I, van der ZJ, Engelborghs S, Wils H et&#x000a0;al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920&#x02013;924</citation></ref><ref id="CR11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>HX</given-names></name><name><surname>Hentati</surname><given-names>A</given-names></name><name><surname>Tainer</surname><given-names>JA</given-names></name><name><surname>Iqbal</surname><given-names>Z</given-names></name><name><surname>Cayabyab</surname><given-names>A</given-names></name><etal/></person-group><article-title>Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>1047</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1126/science.8351519</pub-id></citation><citation citation-type="display-unstructured">Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A et&#x000a0;al (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047&#x02013;1051 <pub-id pub-id-type="pmid">8351519</pub-id></citation></ref><ref id="CR12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filimonenko</surname><given-names>M</given-names></name><name><surname>Stuffers</surname><given-names>S</given-names></name><name><surname>Raiborg</surname><given-names>C</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Malerod</surname><given-names>L</given-names></name><etal/></person-group><article-title>Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease</article-title><source>J Cell Biol</source><year>2007</year><volume>179</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1083/jcb.200702115</pub-id></citation><citation citation-type="display-unstructured">Filimonenko M, Stuffers S, Raiborg C, Yamamoto A, Malerod L et&#x000a0;al (2007) Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol 179:485&#x02013;500 <pub-id pub-id-type="pmid">17984323</pub-id></citation></ref><ref id="CR13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>MS</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>TDP-43: a novel neurodegenerative proteinopathy</article-title><source>Curr Opin Neurobiol</source><year>2007</year><volume>17</volume><fpage>548</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2007.08.005</pub-id></citation><citation citation-type="display-unstructured">Forman MS, Trojanowski JQ, Lee VM (2007) TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol 17:548&#x02013;555 <pub-id pub-id-type="pmid">17936612</pub-id></citation></ref><ref id="CR14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>SH</given-names></name><name><surname>Spires-Jones</surname><given-names>T</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name></person-group><article-title>TAR-DNA binding protein 43 in Pick disease</article-title><source>J Neuropathol Exp Neurol</source><year>2008</year><volume>67</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1097/nen.0b013e3181609361</pub-id></citation><citation citation-type="display-unstructured">Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62&#x02013;67 <pub-id pub-id-type="pmid">18091558</pub-id></citation></ref><ref id="CR15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geser</surname><given-names>F</given-names></name><name><surname>Winton</surname><given-names>MJ</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><etal/></person-group><article-title>Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0257-y</pub-id></citation><citation citation-type="display-unstructured">Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX et&#x000a0;al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133&#x02013;145 <pub-id pub-id-type="pmid">17713769</pub-id></citation></ref><ref id="CR16"><citation citation-type="other">Gijselinck I, Sleegers K, Engelborghs S, Robberecht W, Martin JJ et&#x000a0;al (2007) Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiol Aging</citation></ref><ref id="CR17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gitcho</surname><given-names>MA</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Norton</surname><given-names>JB</given-names></name><etal/></person-group><article-title>TDP-43 A315T mutation in familial motor neuron disease</article-title><source>Ann Neurol</source><year>2008</year><volume>63</volume><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1002/ana.21344</pub-id></citation><citation citation-type="display-unstructured">Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB et&#x000a0;al (2008) TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 63:535&#x02013;538 <pub-id pub-id-type="pmid">18288693</pub-id></citation></ref><ref id="CR18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id></citation><citation citation-type="display-unstructured">Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics. Science 297:353&#x02013;356 <pub-id pub-id-type="pmid">12130773</pub-id></citation></ref><ref id="CR19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Skelton-Robinson</surname><given-names>M</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name></person-group><article-title>The prevalence and causes of dementia in people under the age of 65 years</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><fpage>1206</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.9.1206</pub-id></citation><citation citation-type="display-unstructured">Harvey RJ, Skelton-Robinson M, Rossor MN (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74:1206&#x02013;1209 <pub-id pub-id-type="pmid">12933919</pub-id></citation></ref><ref id="CR20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><etal/></person-group><article-title>TDP-43 is deposited in the Guam parkinsonism-dementia complex brains</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>1386</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1093/brain/awm065</pub-id></citation><citation citation-type="display-unstructured">Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H et&#x000a0;al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386&#x02013;1394 <pub-id pub-id-type="pmid">17439983</pub-id></citation></ref><ref id="CR21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname><given-names>S</given-names></name><name><surname>Iseki</surname><given-names>E</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Minegishi</surname><given-names>M</given-names></name><name><surname>Hino</surname><given-names>H</given-names></name><etal/></person-group><article-title>Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x02019;s disease and dementia with Lewy bodies</article-title><source>Brain Res</source><year>2007</year><volume>1184</volume><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.09.048</pub-id></citation><citation citation-type="display-unstructured">Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H et&#x000a0;al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x02019;s disease and dementia with Lewy bodies. Brain Res 1184:284&#x02013;294 <pub-id pub-id-type="pmid">17963732</pub-id></citation></ref><ref id="CR22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Lendon</surname><given-names>CL</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Froelich</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of missense and 5&#x02032;-splice-site mutations in tau with the inherited dementia FTDP-17</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/31508</pub-id></citation><citation citation-type="display-unstructured">Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S et&#x000a0;al (1998) Association of missense and 5&#x02032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702&#x02013;705 <pub-id pub-id-type="pmid">9641683</pub-id></citation></ref><ref id="CR23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BS</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Gitler</surname><given-names>AD</given-names></name></person-group><article-title>A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>6439</fpage><lpage>6444</lpage><pub-id pub-id-type="doi">10.1073/pnas.0802082105</pub-id></citation><citation citation-type="display-unstructured">Johnson BS, McCaffery JM, Lindquist S, Gitler AD (2008) A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 105:6439&#x02013;6444 <pub-id pub-id-type="pmid">18434538</pub-id></citation></ref><ref id="CR24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kabashi</surname><given-names>E</given-names></name><name><surname>Valdmanis</surname><given-names>PN</given-names></name><name><surname>Dion</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>McConkey</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>572</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/ng.132</pub-id></citation><citation citation-type="display-unstructured">Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ et&#x000a0;al (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40:572&#x02013;574 <pub-id pub-id-type="pmid">18372902</pub-id></citation></ref><ref id="CR25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Yagishita</surname><given-names>A</given-names></name></person-group><article-title>Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging</article-title><source>J Neurol Sci</source><year>1993</year><volume>116</volume><fpage>52</fpage><lpage>58</lpage></citation><citation citation-type="display-unstructured">Kato S, Hayashi H, Yagishita A (1993) Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging. J Neurol Sci 116:52&#x02013;58 <pub-id pub-id-type="pmid">8509805</pub-id></citation></ref><ref id="CR26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis</article-title><source>Neurosignals</source><year>2008</year><volume>16</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1159/000109758</pub-id></citation><citation citation-type="display-unstructured">Kwong LK, Uryu K, Trojanowski JQ, Lee VM (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16:41-51 <pub-id pub-id-type="pmid">18097159</pub-id></citation></ref><ref id="CR27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Geser</surname><given-names>F</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations</article-title><source>Ann Neurol</source><year>2007</year><volume>61</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1002/ana.21147</pub-id></citation><citation citation-type="display-unstructured">Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M et&#x000a0;al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427&#x02013;434 <pub-id pub-id-type="pmid">17469116</pub-id></citation></ref><ref id="CR28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name></person-group><article-title>The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments</article-title><source>Neurogenetics</source><year>2007</year><volume>8</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/s10048-007-0102-4</pub-id></citation><citation citation-type="display-unstructured">Mackenzie IR, Rademakers R (2007) The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 8:237&#x02013;248 <pub-id pub-id-type="pmid">17805587</pub-id></citation></ref><ref id="CR29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Al Chalabi</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>PM</given-names></name><name><surname>Hosler</surname><given-names>B</given-names></name><name><surname>Sapp</surname><given-names>P</given-names></name><etal/></person-group><article-title>A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia</article-title><source>Neurology</source><year>2006</year><volume>66</volume><fpage>839</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000200048.53766.b4</pub-id></citation><citation citation-type="display-unstructured">Morita M, Al Chalabi A, Andersen PM, Hosler B, Sapp P et&#x000a0;al (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66:839&#x02013;844 <pub-id pub-id-type="pmid">16421333</pub-id></citation></ref><ref id="CR30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakashima-Yasuda</surname><given-names>H</given-names></name><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Hurtig</surname><given-names>H</given-names></name><etal/></person-group><article-title>Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0261-2</pub-id></citation><citation citation-type="display-unstructured">Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H et&#x000a0;al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221&#x02013;229 <pub-id pub-id-type="pmid">17653732</pub-id></citation></ref><ref id="CR31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>JS</given-names></name><name><surname>Gustafson</surname><given-names>L</given-names></name><name><surname>Passant</surname><given-names>U</given-names></name><name><surname>Stuss</surname><given-names>D</given-names></name><etal/></person-group><article-title>Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>1546</fpage><lpage>1554</lpage></citation><citation citation-type="display-unstructured">Neary D, Snowden JS, Gustafson L, Passant U, Stuss D et&#x000a0;al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546&#x02013;1554 <pub-id pub-id-type="pmid">9855500</pub-id></citation></ref><ref id="CR32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>130</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1126/science.1134108</pub-id></citation><citation citation-type="display-unstructured">Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC et&#x000a0;al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130&#x02013;133 <pub-id pub-id-type="pmid">17023659</pub-id></citation></ref><ref id="CR33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Vanmassenhove</surname><given-names>B</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><etal/></person-group><article-title>TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions</article-title><source>J Neuropathol Exp Neurol</source><year>2007</year><volume>66</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000248554.45456.58</pub-id></citation><citation citation-type="display-unstructured">Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA et&#x000a0;al (2007) TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 66:177&#x02013;183 <pub-id pub-id-type="pmid">17356379</pub-id></citation></ref><ref id="CR34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Harrich</surname><given-names>D</given-names></name><name><surname>Garcia-Martinez</surname><given-names>LF</given-names></name><name><surname>Gaynor</surname><given-names>RB</given-names></name></person-group><article-title>Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs</article-title><source>J Virol</source><year>1995</year><volume>69</volume><fpage>3584</fpage><lpage>3596</lpage></citation><citation citation-type="display-unstructured">Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69:3584&#x02013;3596 <pub-id pub-id-type="pmid">7745706</pub-id></citation></ref><ref id="CR35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasinelli</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>RH</given-names></name></person-group><article-title>Molecular biology of amyotrophic lateral sclerosis: insights from genetics</article-title><source>Nat Rev Neurosci</source><year>2006</year><volume>7</volume><fpage>710</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1038/nrn1971</pub-id></citation><citation citation-type="display-unstructured">Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7:710&#x02013;723 <pub-id pub-id-type="pmid">16924260</pub-id></citation></ref><ref id="CR36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pickering-Brown</surname><given-names>SM</given-names></name><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>PD</given-names></name><name><surname>Morrison</surname><given-names>KE</given-names></name><name><surname>Varma</surname><given-names>A</given-names></name><etal/></person-group><article-title>Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>721</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1093/brain/awm331</pub-id></citation><citation citation-type="display-unstructured">Pickering-Brown SM, Rollinson S, Du PD, Morrison KE, Varma A et&#x000a0;al (2008) Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 131:721&#x02013;731 <pub-id pub-id-type="pmid">18192287</pub-id></citation></ref><ref id="CR37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poorkaj</surname><given-names>P</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Wijsman</surname><given-names>E</given-names></name><name><surname>Nemens</surname><given-names>E</given-names></name><name><surname>Garruto</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Tau is a candidate gene for chromosome 17 frontotemporal dementia</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1002/ana.410430617</pub-id></citation><citation citation-type="display-unstructured">Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM et&#x000a0;al (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43:815&#x02013;825 <pub-id pub-id-type="pmid">9629852</pub-id></citation></ref><ref id="CR38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ratnavalli</surname><given-names>E</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>K</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name></person-group><article-title>The prevalence of frontotemporal dementia</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>1615</fpage><lpage>1621</lpage></citation><citation citation-type="display-unstructured">Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615&#x02013;1621 <pub-id pub-id-type="pmid">12058088</pub-id></citation></ref><ref id="CR39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>J</given-names></name><name><surname>Sanelli</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Horne</surname><given-names>P</given-names></name><etal/></person-group><article-title>Lack of TDP-43 abnormalities in mutant <italic>SOD1</italic> transgenic mice shows disparity with ALS</article-title><source>Neurosci Lett</source><year>2007</year><volume>420</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.03.066</pub-id></citation><citation citation-type="display-unstructured">Robertson J, Sanelli T, Xiao S, Yang W, Horne P et&#x000a0;al (2007) Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett 420:128&#x02013;132 <pub-id pub-id-type="pmid">17543992</pub-id></citation></ref><ref id="CR40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Snowden</surname><given-names>JS</given-names></name><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Morrison</surname><given-names>KE</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><etal/></person-group><article-title>TDP-43 gene analysis in frontotemporal lobar degeneration</article-title><source>Neurosci Lett</source><year>2007</year><volume>419</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.03.044</pub-id></citation><citation citation-type="display-unstructured">Rollinson S, Snowden JS, Neary D, Morrison KE, Mann DM et&#x000a0;al (2007) TDP-43 gene analysis in frontotemporal lobar degeneration. Neurosci Lett 419:1&#x02013;4 <pub-id pub-id-type="pmid">17434264</pub-id></citation></ref><ref id="CR41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>DR</given-names></name><name><surname>Siddique</surname><given-names>T</given-names></name><name><surname>Patterson</surname><given-names>D</given-names></name><name><surname>Figlewicz</surname><given-names>DA</given-names></name><name><surname>Sapp</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis</article-title><source>Nature</source><year>1993</year><volume>362</volume><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/362059a0</pub-id></citation><citation citation-type="display-unstructured">Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P et&#x000a0;al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59&#x02013;62 <pub-id pub-id-type="pmid">8446170</pub-id></citation></ref><ref id="CR42"><citation citation-type="other">Schumacher A, Friedrich P, Diehl-Schmid J, Ibach B, Perneczky R et&#x000a0;al (2007) No association of TDP-43 with sporadic frontotemporal dementia. Neurobiol Aging</citation></ref><ref id="CR43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schymick</surname><given-names>JC</given-names></name><name><surname>Talbot</surname><given-names>K</given-names></name><name><surname>Traynor</surname><given-names>BJ</given-names></name></person-group><article-title>Genetics of sporadic amyotrophic lateral sclerosis</article-title><source>Hum Mol Genet 16 Spec No</source><year>2007</year><volume>2</volume><fpage>R233</fpage><lpage>R242</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm215</pub-id></citation><citation citation-type="display-unstructured">Schymick JC, Talbot K, Traynor BJ (2007) Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16 Spec No. 2:R233&#x02013;R242 </citation></ref><ref id="CR44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Parkinson</surname><given-names>NJ</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Chakrabarti</surname><given-names>L</given-names></name><name><surname>Lloyd</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>806</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/ng1609</pub-id></citation><citation citation-type="display-unstructured">Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL et&#x000a0;al (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806&#x02013;808 <pub-id pub-id-type="pmid">16041373</pub-id></citation></ref><ref id="CR45"><citation citation-type="other">Sleegers K, Brouwers N, Maurer-Stroh S, van Es MA, Van Damme P et&#x000a0;al (2008) Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology</citation></ref><ref id="CR46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Murrell</surname><given-names>JR</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Klug</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mutation in the tau gene in familial multiple system tauopathy with presenile dementia</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>7737</fpage><lpage>7741</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7737</pub-id></citation><citation citation-type="display-unstructured">Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A et&#x000a0;al (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95:7737&#x02013;7741 <pub-id pub-id-type="pmid">9636220</pub-id></citation></ref><ref id="CR47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sreedharan</surname><given-names>J</given-names></name><name><surname>Blair</surname><given-names>IP</given-names></name><name><surname>Tripathi</surname><given-names>VB</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Vance</surname><given-names>C</given-names></name><etal/></person-group><article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis</article-title><source>Science</source><year>2008</year><volume>319</volume><fpage>1668</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1126/science.1154584</pub-id></citation><citation citation-type="display-unstructured">Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C et&#x000a0;al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668&#x02013;1672 <pub-id pub-id-type="pmid">18309045</pub-id></citation></ref><ref id="CR48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CF</given-names></name><name><surname>Eguchi</surname><given-names>H</given-names></name><name><surname>Tagawa</surname><given-names>A</given-names></name><name><surname>Onodera</surname><given-names>O</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without <italic>SOD1</italic> gene mutation</article-title><source>Acta Neuropathol</source><year>2007</year><volume>113</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0206-9</pub-id></citation><citation citation-type="display-unstructured">Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T et&#x000a0;al (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 113:535&#x02013;542 <pub-id pub-id-type="pmid">17333220</pub-id></citation></ref><ref id="CR49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valdmanis</surname><given-names>PN</given-names></name><name><surname>Dupre</surname><given-names>N</given-names></name><name><surname>Bouchard</surname><given-names>JP</given-names></name><name><surname>Camu</surname><given-names>W</given-names></name><name><surname>Salachas</surname><given-names>F</given-names></name><etal/></person-group><article-title>Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.2.240</pub-id></citation><citation citation-type="display-unstructured">Valdmanis PN, Dupre N, Bouchard JP, Camu W, Salachas F et&#x000a0;al (2007) Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol 64:240&#x02013;245 <pub-id pub-id-type="pmid">17296840</pub-id></citation></ref><ref id="CR50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valdmanis</surname><given-names>PN</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name></person-group><article-title>Genetics of familial amyotrophic lateral sclerosis</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000296811.19811.db</pub-id></citation><citation citation-type="display-unstructured">Valdmanis PN, Rouleau GA (2008) Genetics of familial amyotrophic lateral sclerosis. Neurology 70:144&#x02013;152 <pub-id pub-id-type="pmid">18180444</pub-id></citation></ref><ref id="CR51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deerlin</surname><given-names>VM</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Bekris</surname><given-names>LM</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><etal/></person-group><article-title>TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70071-1</pub-id></citation><citation citation-type="display-unstructured">Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W et&#x000a0;al (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7:409&#x02013;416 <pub-id pub-id-type="pmid">18396105</pub-id></citation></ref><ref id="CR52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>GD</given-names></name><name><surname>Wymer</surname><given-names>J</given-names></name><name><surname>Kovach</surname><given-names>MJ</given-names></name><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Mumm</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/ng1332</pub-id></citation><citation citation-type="display-unstructured">Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S et&#x000a0;al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36:377&#x02013;381 <pub-id pub-id-type="pmid">15034582</pub-id></citation></ref><ref id="CR53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winton</surname><given-names>MJ</given-names></name><name><surname>Igaz</surname><given-names>LM</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>13302</fpage><lpage>13309</lpage><pub-id pub-id-type="doi">10.1074/jbc.M800342200</pub-id></citation><citation citation-type="display-unstructured">Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ et&#x000a0;al (2008) Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation. J Biol Chem 283:13302-13309 <pub-id pub-id-type="pmid">18305110</pub-id></citation></ref><ref id="CR54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokoseki</surname><given-names>A</given-names></name><name><surname>Shiga</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>CF</given-names></name><name><surname>Tagawa</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><etal/></person-group><article-title>TDP-43 mutation in familial amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><year>2008</year><volume>63</volume><fpage>538</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1002/ana.21392</pub-id></citation><citation citation-type="display-unstructured">Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H et&#x000a0;al (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 63:538&#x02013;542 <pub-id pub-id-type="pmid">18438952</pub-id></citation></ref></ref-list></back></article> 